ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 83 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,662,975 | -33.9% | 242,770 | +0.1% | 0.00% | -100.0% |
| Q2 2023 | $2,513,957 | +34.9% | 242,426 | +5.3% | 0.00% | – |
| Q1 2023 | $1,862,885 | -48.9% | 230,270 | -0.6% | 0.00% | -100.0% |
| Q4 2022 | $3,647,905 | -0.9% | 231,613 | -1.0% | 0.00% | 0.0% |
| Q3 2022 | $3,682,000 | +30.5% | 233,882 | +15.7% | 0.00% | 0.0% |
| Q2 2022 | $2,822,000 | -11.8% | 202,199 | +8.9% | 0.00% | 0.0% |
| Q1 2022 | $3,200,000 | +18.1% | 185,596 | -0.4% | 0.00% | – |
| Q4 2021 | $2,709,000 | -17.4% | 186,322 | +2.2% | 0.00% | -100.0% |
| Q3 2021 | $3,281,000 | +38.1% | 182,245 | +34.8% | 0.00% | – |
| Q2 2021 | $2,375,000 | -15.2% | 135,242 | +21.7% | 0.00% | -100.0% |
| Q1 2021 | $2,801,000 | +313.7% | 111,156 | +6.2% | 0.00% | – |
| Q4 2020 | $677,000 | +140.9% | 104,619 | -4.2% | 0.00% | – |
| Q3 2020 | $281,000 | +59.7% | 109,213 | 0.0% | 0.00% | – |
| Q2 2020 | $176,000 | -22.5% | 109,213 | -49.9% | 0.00% | – |
| Q1 2020 | $227,000 | -45.3% | 217,783 | -0.9% | 0.00% | – |
| Q4 2019 | $415,000 | +209.7% | 219,779 | +76.9% | 0.00% | – |
| Q3 2019 | $134,000 | -63.0% | 124,252 | -24.8% | 0.00% | – |
| Q2 2019 | $362,000 | -70.5% | 165,209 | -19.3% | 0.00% | – |
| Q1 2019 | $1,226,000 | -16.2% | 204,830 | +3.4% | 0.00% | – |
| Q4 2018 | $1,463,000 | -76.1% | 198,036 | -53.0% | 0.00% | -100.0% |
| Q3 2018 | $6,116,000 | -27.6% | 421,199 | -0.4% | 0.00% | 0.0% |
| Q2 2018 | $8,447,000 | +23.1% | 423,001 | +8.0% | 0.00% | 0.0% |
| Q1 2018 | $6,862,000 | +2.1% | 391,662 | +43.8% | 0.00% | 0.0% |
| Q4 2017 | $6,718,000 | +136.6% | 272,404 | +147.6% | 0.00% | +100.0% |
| Q3 2017 | $2,839,000 | +18.6% | 110,015 | +24.6% | 0.00% | 0.0% |
| Q2 2017 | $2,393,000 | -9.0% | 88,261 | +0.1% | 0.00% | 0.0% |
| Q1 2017 | $2,630,000 | -15.6% | 88,184 | -23.2% | 0.00% | 0.0% |
| Q4 2016 | $3,115,000 | +160.0% | 114,777 | +145.6% | 0.00% | – |
| Q3 2016 | $1,198,000 | +83.7% | 46,733 | +32.6% | 0.00% | – |
| Q2 2016 | $652,000 | +121.8% | 35,255 | +127.1% | 0.00% | – |
| Q1 2016 | $294,000 | -23.6% | 15,521 | +8.7% | 0.00% | – |
| Q4 2015 | $385,000 | – | 14,283 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |